Monogenic Diabetes Modeling: *In Vitro* Pancreatic Differentiation From Human Pluripotent Stem Cells Gains Momentum

Juan Ignacio Burgos1, Ludovic Vallier2* and Santiago A. Rodríguez-Seguí1*

1 Departamento de Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires and Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE), CONICET-Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina, 2 Wellcome-Medical Research Council Cambridge Stem Cell Institute and Department of Surgery, University of Cambridge, Cambridge, United Kingdom

The occurrence of diabetes mellitus is characterized by pancreatic β cell loss and chronic hyperglycemia. While Type 1 and Type 2 diabetes are the most common types, rarer forms involve mutations affecting a single gene. This characteristic has made monogenic diabetes an interesting disease group to model *in vitro* using human pluripotent stem cells (hPSCs). By altering the genotype of the original hPSCs or by deriving human induced pluripotent stem cells (hiPSCs) from patients with monogenic diabetes, changes in the outcome of the *in vitro* differentiation protocol can be analyzed in detail to infer the regulatory mechanisms affected by the disease-associated genes. This approach has been so far applied to a diversity of genes/diseases and uncovered new mechanisms. The focus of the present review is to discuss the latest findings obtained by modeling monogenic diabetes using hPSC-derived pancreatic cells generated *in vitro*. We will specifically focus on the interpretation of these studies, the advantages and limitations of the models used, and the future perspectives for improvement.

**Keywords**: pancreas, beta cell, human, pluripotent stem cell, monogenic, modeling, diabetes, *in vitro* differentiation

**INTRODUCTION**

Diabetes mellitus (DM) is characterized by pancreatic β cell loss and chronic hyperglycemia. Type 1 diabetes (T1D) is caused by the autoimmune reaction against β cells (1), and Type 2 diabetes originates from insulin resistance and β cell overload (2–4). In addition, rarer monogenic forms of diabetes account for approximately 1–5% of diabetes cases, depending on the population studied (5, 6). Over 30 subtypes of monogenic diabetes have been identified to date, each having a characteristic phenotype and a specific pattern of inheritance (6, 7). The identification of genes implicated in the pathogenesis of monogenic diabetes, including components of the insulin secretory pathway and transcription factors, has provided important insights into human pancreas and β cell development and function.

Monogenic diabetes is caused by either splice-site, non-sense, missense, or frame-shift mutations, and more rarely partial or full deletions, affecting a single gene (8–14). The disease...
phenotype and associated extra-pancreatic features vary depending on the affected gene (15). These characteristics have made monogenic diabetes an interesting disease subtype to model using human pluripotent stem cells (hPSCs). Indeed, hPSCs can be differentiated into pancreatic cells following key steps of differentiation induced by well-established combinations of growth factors and small molecules, thereby respecting a natural path of development [recently reviewed in (16, 17)]. Thus, differentiation of human induced pluripotent stem cells (hiPSCs) either derived from patients with monogenic diabetes or genetically edited to carry the mutation of interest can be used to study the potential regulatory mechanisms affected by each of the disease-associated genes (Figure 1). Applying this approach to a diversity of genes has led to the discovery of new mechanisms associated with specific regulators of pancreatic development. The focus of this review is to discuss the latest findings obtained by modeling monogenic diabetes using hPSC-derived pancreatic cells generated in vitro. We will focus on the interpretation of these studies, the advantages and limitations of the models used, and the future perspectives for improvement. Of note, the reader is referred to recent reviews concerning: 1) the state-of-the-art knowledge in pancreatic β cell development in mice and humans (18–21); 2) the tools for hPSC genome editing (22, 23); 3) a comparison of the in vitro pancreatic differentiation protocols including the latest advances to achieve functional β cells from hPSCs (16, 17, 24); 4) analyzing the intrinsic variation in the protocol outcomes from different sources of hPSCs (25, 26); and 5) the use of in vitro pancreatic differentiation from hPSCs to discover new mechanisms underlying human pancreas development (24, 27), or to model other types of diabetes (23, 28–31). The later also summarize findings on monogenic diabetes modeling. Our review adds up on top of these by exclusively focusing on the modeling of monogenic diabetes, discussing in more detail the different approaches taken and including extremely recent works which provide insightful information for the interpretation of the results published so far.

**HUMAN PANCREAS DEVELOPMENT**

**Lessons Learned From Mice and Current Challenges**

Pancreas development begins with the establishment of the pancreatic bud containing multipotent pancreatic progenitor cells (MPCs) at ~E8.5 in the mouse (19, 20) or ~29 days post conception in humans (20, 21, 32) and progresses until E18.5 in the mouse (19, 20) or 24 weeks post conception (wpc) estimated in humans (20, 21, 33–35). By this time, most of the pancreatic progenitor cells are terminally fate-committed. The MPCs are capable of differentiating along the three main lineages of the adult pancreas, namely the ductal, the exocrine (comprising acinar cells that secrete digestive enzymes), and the endocrine (including the β cells that produce insulin, but also the α, δ, γ and PP cells) (19, 36, 37). As the pancreas develops, MPCs differentiate into acinar or endocrine-ductal bipotent progenitor.
(BP) cells, and eventually to endocrine-committed progenitors (EPCs) that will give rise to β cells. Importantly, recent single cell RNA-seq (scRNA-seq) studies have described the transcriptional profiles that characterize these pancreatic progenitor cell stages in the mouse and identified additional progenitor cell sub stages (38–42). Thus, we can now rely on a precise transcriptomic fingerprint for several progenitors that arise during mouse pancreas development.

Cumulative knowledge has revealed the role and stage-specific functions of signaling pathways in the pancreatic developmental program, including Wnt, TGF-β, Notch, FGF and, more recently, the Hippo pathway (19, 36, 37, 43–46). The pancreatic mesenchyme has also been shown to play important roles during development, by fine-tuning the crosstalk with the pancreatic epithelium through these pathways (47–50). This knowledge has been exploited to develop protocols to differentiate human embryonic stem cells (hESCs) into the pancreatic lineage (51–55), opening the possibility to produce large quantities of β cells for cell-based therapies and also providing a new avenue for research in human pancreas development.

Differentiation protocols currently available to produce β cells from hPSCs take advantage of the cell signaling events that occur during fetal development (18–21). Despite this knowledge-based approach, the generation of fully functional β cells in vitro has remained elusive. We thus refer to the cells produced in vitro so far as β-like cells. This limitation could be in part explained by the fact that the function of these pathways during pancreas development has been mainly studied in rodents, and it has recently been reported that human pancreas development could differ in several aspects (20, 21, 32, 56, 57). We are still lacking systematic studies comparing islet development between human and mouse, although recent reports are moving forward to address this gap (57–60). It is expected that a deeper understanding of these inter-species differences in islet development will probably be critical for the production of fully functional and mature β cells from hPSCs. As well, this will allow a more precise dissection of the molecular mechanisms driving diabetes predisposition by genetic mutations and/or external stimuli. Noteworthy, recent protocols allow the derivation of monohormonal insulin-producing cells expressing key β cell transcription factors, including PDX1, NKK6.1, and MAFA (61–65). Fine tuning of such protocols could further improve the glucose-response of in vitro derived β-like cells (66–69) without the need to involve a step of cell transplantation in mice to ensure proper maturation.

Lessons Learned From In Vitro Human PSC Pancreatic Differentiation

The use of hPSCs as in vitro model system to study human pancreatic development has gained momentum and several important discoveries have been made using this approach [recently reviewed in (27)].

A Role for TEAD and YAP in Pancreas Development

By comparing the transcriptomes and key epigenomic features of MPCs derived in vitro from hESCs with human fetal primary pancreatic tissue of six wpc embryos, we were able to show that in vitro derived cells closely recapitulated the main expression profile and regulatory landscape of their in vivo counterparts (45). Furthermore, this epigenomic characterization was extended to include ChIP-seq profiling of several transcription factors by taking advantage of the in vitro system. A combined analysis of these data led to the discovery that TEAD1 was an integral component of the enhancer network in human embryonic pancreatic progenitors (45, 46). The relevance of TEAD protein binding for the activation of MPC enhancers was mechanistically validated using the platform provided by hPSC-derived pancreatic cells in vitro. We concluded that, while highly tissue specific enhancers were defined by co-binding of pancreas-specific transcription factors, TEAD proteins conferred these regions the ability to be regulated by YAP (an effector of the Hippo pathway) during human pancreas development. These results were consistent with reports for a role of the Hippo pathway in mouse pancreas development (43, 44). More recent reports support these findings by showing that YAP and other components of the Hippo pathway are active and highly enriched within the SOX9+/PTF1A+ progenitor cells of the human fetal pancreas (58).

The human in vitro differentiation system has provided additional mechanistic evidence for the relevance of the Hippo pathway in pancreas differentiation by showing that YAP links extracellular matrix-mediated mechano-signals to regulate gene expression. Integration of such signaling plays a key role in the fate choice of bipotent pancreatic progenitors, whereby YAP downregulation favors endocrine cell commitment (70). In agreement, sustained in vitro YAP activation impairs β cell differentiation while inhibition of YAP enhances differentiation of functional β cells derived from hPSCs (71). Combined together, these results illustrate how in vitro pancreatic differentiation can help in the discovery of new regulatory mechanisms that are relevant for human β cell development.

A Role for Polycomb Group-Mediated Repression in Pancreas Development

Mapping the dynamic changes in histone modifications and chromatin accessibility across different stages of the in vitro pancreatic differentiation protocol has provided important insights into the suitability and current limitations of this model (72–75). It has to be noted that, despite successful applications, the in vitro pancreatic differentiation system does not exactly replicate all the epigenomic features of their in vivo counterparts. Sander and colleagues have profiled selected chromatin modifications and the transcriptome of these cells, at different stages of the pancreatic endocrine differentiation protocol using hESCs (72). They showed that removal of Polycomb group (PcG)-mediated repression on stage-specific genes was a key mechanism for the induction of developmental regulators in the in vitro system, consistent with the in vivo relevance of this mechanism in mouse endocrine pancreas development (76–78). However, they also reported that elimination of PcG-mediated repression on endocrine-specific genes was not fully recapitulated by the in vitro derived endocrine cells. This was particularly evident at genes involved in organ morphogenesis, underscoring a current limitation.
(i.e. the lack of tissue-specific contextual cell signaling) of the in vitro protocols for studying some aspects of in vivo development. Noteworthy, these experiments were performed using 2D in vitro differentiation protocols which have been shown to be less efficient to produce functional β-like cells than three-dimensional suspension culture systems (61–63, 66–68). This “second generation” protocols could be more efficient in allowing the proper deposition of epigenetic marks.

Distinct Progenitor Cell Populations Could Differentiate Into Monohormonal β Cells

Another example of the complexity of the in vitro endocrine differentiation process was provided by Petersen et al. who profiled single-cell transcripts by qRT-PCR at selected stages of the protocol used to produce β-like cells from hPSCs (79). This analysis identified two distinct progenitor cell populations with the potential to differentiate into monohormonal β-like cells. NKX6.1 expression prior or after the onset of NEUROG3 (the gene coding for the EP transcription factor marker NGN3) was the main difference between these progenitors. Building up on these results, Ramond et al. performed a combined analysis of single-cell qRT-PCR datasets obtained from pancreatic progenitor and endocrine cells from in vitro and in vivo samples (59, 60). Their observations suggest that these distinct progenitor cell populations identified in vitro could indeed exist during in vivo development. This finding contrasts with knowledge gained from mouse studies where Nkx6 factors systematically specify endocrine cell fate upstream of Ngn3 in the MPC stage (80, 81). Still, the function and characteristics of these two populations of progenitors in the developing human pancreas remain to be fully elucidated.

Taking advantage of novel single-cell technologies can help to match some of the transcriptional signatures from in vivo pancreatic progenitor cell stages identified in the mouse (38–41), with pancreatic progenitors derived from hPSCs (38, 66, 82). However, such exercise remains challenging due to inter-species differences and also the impact of the in vitro culture. New tools are being quickly developed to address this limitation, making the bioinformatic analyses of these data an exciting area of research (83, 84). More recently, the first scRNA-seq experiments using human embryonic pancreas from 15.2 and 17.1 wpc have been reported (58, 85). Integration of these scRNA-seq datasets with those derived from the mouse embryonic pancreas will help to identify differences and similarities in the transcriptional fingerprints of the distinct pancreatic progenitor cell types. This will ultimately contribute to validate the identity of pancreatic progenitors produced from hPSCs.

MODELING MONOGENIC DIABETES WITH HUMAN PLURIPOTENT STEM CELLS

The most frequently affected maturity-onset diabetes of the young (MODY) genes include the enzyme glucokinase (GCK, MODY2) (86, 87) and the transcription factor genes hepatic nuclear factor 1 alpha (HNF1A, MODY3) (88), hepatic nuclear factor 4 alpha (HNF4A, MODY1) (89), and hepatic nuclear factor 1 beta (HNF1B, MODY5) (90). Other MODY genes include PDX1 (MODY4), NEUROD1 (MODY6), KLF11 (MODY7), CEL (MODY8), PAX4 (MODY9), INS (MODY10), BLK (MODY11), ABCBC8 (MODY12), KCNJ11 (MODY13), APP1L (MODY14) (91). On the other hand, homozygous mutations at several lineage determining transcription factors, such as PTF1A, PDX1, NEUROG3, RFX6, NEUROD1, MNX1, NKX2.2 and GLIS3 result in permanent neonatal diabetes mellitus (PNDM) in humans (13, 92–100). Interestingly, heterozygous mutations in these genes rarely result in diabetes in mice, thereby suggesting an important divergence in the activity or function for these factors between human and mouse (19, 21, 101). The importance of haploinsufficiency and the mechanisms by which a decrease in transcription factor activity causes a disease in humans is poorly understood, mostly due to the lack of an appropriate model system. As an example, MODY5 diabetes (HNF1B-associated) can be induced by a diversity of mutations including several splice-site, non-sense, missense, and frame-shift mutations or whole gene deletions, all of which result in a diabetes (102). The heterozygous mutation in mouse has no effect on pancreatic development, while homozygous mutation blocks foregut specification thereby masking its downstream function in the differentiation of MPCs. Ultimately, haploinsufficiency may reflect the functional effects of different gene anomalies, stochastic variation in temporal gene expression during early development or additional genetic and/or environmental modifiers that may influence the disease phenotype (102–104).

As mentioned above, mouse models often do not recapitulate the disease phenotype associated with heterozygous mutations of HNF1A, HNF4A, or HNF1B in humans. The genetic discrepancy between the mouse and monogenic diabetes gene haploinsufficient patients and the difficulty in accessing patient samples have reinforced the interest in using hPSCs (Figure 1). Genome-editing tools combined with directed differentiation of hPSCs offer a unique platform for generating patient-specific disease models to elucidate novel genes and molecular pathways that underlie monogenic diseases with complex traits, such as diabetes, and ultimately lead to the development of novel therapeutic strategies [recently reviewed in (22, 25)]. Several studies in the last decade have used genetically engineered hPSC culture systems for differentiation into pancreatic cells to further expand our understanding of the roles of various genes associated with monogenic diabetes. Their findings are summarized in Tables 1, 2, and these will be discussed in more detail next.

WFS1

Egli and colleagues provided the first example for the use of hiPSCs to create insulin-producing cells from patients with Wolfram Syndrome (WS) (119). hiPSCs were generated from individuals with diabetes caused by mutations in the WFS1 gene and healthy-donor controls. Differentiation of these cells towards β-like cells revealed increased levels of ER stress molecules and decreased insulin content in WFS1-deficient β-like cells. Overall, insulin processing and secretion in response to various
### TABLE 1 | Summary of reports modeling maturity-onset diabetes of the young (MODY) mutation effects.

| Gene studied | Pancreatic defects reported in humans | Effects recapitulated in mice | Genome editing approach | Differentiation protocol | Type of human pluripotent stem cell | In vitro phenotypes | Ref. |
|--------------|-------------------------------------|-----------------------------|-------------------------|--------------------------|-----------------------------------|---------------------|------|
| **HNF4A (MODY1)** | HNF4A heterozygous mutations affect both liver and pancreas development. MODY1 patients present neonatal hyperinsulinemia and impairment in β cell function. They present normal insulin sensitivity but decreased insulin secretion. | Rodent models do not accurately recapitulate the MODY1 phenotype in humans. The available Hnf4a general knockout murine model is embryonic lethal, while heterozygous mice present normal glucose tolerance and do not show any diabetic features. | NA | (62) | hiPSCs were derived from MODY1 mutation carriers. Their family members, without the mutation, were used as controls. Control hiPSC lines (CSES7 and IPSO lines) and MODY1 patient-derived hiPSCs. | The HNF4A mutation studied did not prevent the formation of insulin+ cells in vitro. Also, no defects in β-like cells differentiated from HNF4A mutant hiPSCs were found. | (105) |
| **GCK (MODY2)** | Patients with GCK heterozygous mutations present progressive β-cell dysfunction, fasting hyperglycemia and reduced insulin secretion. These result in a mild diabetes phenotype, that generally does not require anti-diabetes medication. | Homozygous mutant mice exhibit growth retardation and die soon after birth as consequence of severe hyperglycemia. Heterozygous mutant mice only present slightly elevated blood glucose levels from birth, with disturbed glucose tolerance and glucose-induced insulin secretion. | NA | na | Non-edited MODY2 and PNDM patient-derived hiPSCs. | Key developmental genes such as HNF1B, PDX1, GATA4, and RFX6 are downregulated at the foregut progenitor stage, prior to MPC specification. Still, terminally differentiated β-like cells can be produced and express selective β cell markers and C-peptide. The functional capacity of these cells could not be appropriately elucidated due to limitations of the in vitro protocol used. | (107) |
| **HNF1A (MODY3)** | Patients with HNFA1 heterozygous mutations show β cell dysfunction and hyperglycemia due to insufficient insulin release in response to increased blood glucose levels. | Mouse models do not fully mimic the human disease phenotype. Mice with heterozygous mutations in Hnf1a are healthy and mice with homozygous null mutations present a diabetic phenotype. | CRISPR-CAS9 system. | (62), with minor modifications. | Genome-edited hESCs (MEL1 and H1) and human β-cell lines (EndoC-BH). | Differentiation from HNF1A+/− hESCs show reduced number of INS+ cells. β-like cells present defects in mitochondrial function and the glycolysis process. Decreased expression of β cell transcription factors and genes associated with insulin synthesis. Reduced β cell proliferation and increased apoptosis. HNF1A MODY3 mutations caused decreased GLUT2 expression, which was associated with reduced glucose uptake and ATP production. The mutant HNF1A β-like cells present decreased insulin secretion in response to high glucose. | (109) |

(Continued)
secretagogues was comparable to healthy controls, but the former displayed increased activity of unfolded protein response (UPR) pathways.

More recently, Maxwell et al. used CRISPR/Cas9 to correct a diabetes-causing pathogenic variant in WFS1 hiPSCs (120). Noteworthy, β-like cells differentiated from WFS1-corrected hiPSCs showed robust and dynamic insulin secretion in response to glucose, and reversed streptozocin-induced diabetes when transplanted into mice. Single-cell RNA-seq transcriptome profiling showed that indeed these cells displayed increased insulin levels and decreased expression of genes associated with endoplasmic reticulum stress. Taken together, these studies illustrate the potential of in vitro pancreatic differentiation from hPSCs to study how mechanisms related to cellular stress can affect diabetes onset.

**PDX1**

Homozygous null mutations in PDX1 result in pancreatic agenesis both in mice and humans (13, 121–123). Human patients with PDX1 heterozygous inactivating mutations exhibit MODY4 diabetes caused by defects in β cell function and/or the maintenance of β cell mass (36). In rodents, it has been reported that Pdx1+/- mice can develop a functional pancreas (121, 122) but become diabetic in adulthood due to β cell apoptosis (124).

Another pioneer study to model monogenic diabetes was reported by Huangfu and colleagues, who used TALEN and CRISPR-Cas-mediated gene editing combined with hPSC-directed differentiation. These researchers provide a systematic analysis of the role for PDX1 and seven additional pancreatic transcription factors (RFX6, PTF1A, GLIS3, MNX1, NGN3, HES1 and ARX) in pancreatic cell commitment (111). Noteworthy, they created mono- or biallelic frameshift mutations in all these genes and used untargeted isogenic cell lines as controls. This analysis not only defined the specific developmental steps affected by these mutations in a model of human pancreas differentiation, but also revealed new mechanisms. Tables 1, 2 show a summary of their results for the genes previously associated with MODY and/or PNDM. An interesting finding of this work was that monoallelic frameshift translation mutations disrupting the PDX1 protein sequence cause a reduction (up to 65%) in the number of INS+ cells derived in vitro. Monoallelic PDX1 mutations are associated with decreased PDX1 protein expression. These compromise endocrine differentiation and lead to reduction in the number of INS+ cells derived in vitro. Heterozygous mutations impair in vitro β cell differentiation and function. Homozygous point mutations in the PDX1 transactivation domain do not only impair pancreatic endocrine lineage development, but also impair glucose-responsive function of β cells through misregulation of several PDX1 target genes. Upregulation of multiple key pancreatic transcription factors at the DE and MPC stage, including FOXA2, PDX1, GATA4 and GATA6. Interestingly, expression of HNF1B itself was induced in mutant hPSC-derived MPCs. Reduction of PAX6 expression.

### TABLE 1 | Continued

| Gene studied | Pancreatic defects reported in humans | Effects recapitulated in mice | Genome editing approach | Differentiation protocol | Type of human pluripotent stem cell | **In vitro phenotypes** | Ref. |
|--------------|--------------------------------------|-----------------------------|-------------------------|-------------------------|--------------------------------------|-------------------------|------|
| **PDX1** (MODY4) | PDX1 heterozygous mutations are associated with insulin secretion deficiency. Common point heterozygous mutations in the PDX1 transactivation domain impair human pancreatic β cell formation and function, and contribute to increased risk for diabetes. Pancreatic developmental anomalies related to PDX1 mutations are reported only in neonatal diabetes cases. | Homozygous Pdx1- deficient mice fail to generate a pancreas, while heterozygous animals develop a pancreas but become diabetic in adulthood due to β cell apoptosis. | TALEN and CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). | Monoallelic PDX1 mutations are associated with decreased PDX1 protein expression. These compromise endocrine differentiation and lead to reduction in the number of INS+ cells derived in vitro. | (111) |
| **HNF1B** (MODY5) | Patients with HNF1B heterozygous mutations commonly exhibit pancreatic hypoplasia, β-cell dysfunction and insulin resistance. | Hnf1b−/− mice present pancreatic agenesis, exhibiting loss of expression of several pancreatic genes, including Pdx6, which regulate β-cell function. In contrast with MODY5 patients, Hnf1b+/- mice do not develop diabetes. | CRISPR/Cas9. | Based on (62). | Genome-edited hiPSCs and patient-derived hiPSCs. | Heterozygous mutations impair in vitro β cell differentiation and function. Homozygous point mutations in the PDX1 transactivation domain do not only impair pancreatic endocrine lineage development, but also impair glucose-responsive function of β cells through misregulation of several PDX1 target genes. | (112) |

**NA**, not applicable.
### TABLE 2 | Summary of reports modeling monogenic mutations associated with permanent neonatal diabetes mellitus (PNDM) or pancreatic agenesis.

| Gene studied | Pancreatic defects reported in humans | Effects recapitulated in mice | Genome editing approach | Differentiation protocol | Type of human pluripotent stem cell | In vitro phenotypes | Ref. |
|--------------|--------------------------------------|-----------------------------|-------------------------|--------------------------|-------------------------------|-------------------|------|
| **GATA6**    | GATA6 heterozygous inactivating mutations result in pancreatic agenesis. Gata6 heterozygous mice are fertile and phenotypically normal. Gata6 null mice are embryonic lethal. Biallelic loss of Gata6 and its paralog Gata4 result in a phenotype similar to human PNDM GATA6-mutated patients. | GATA6 heterozygous mutations lead to impaired DE differentiation. Rescue of DE defects in these cells by re-expression of other GATA family members allows β-like cell production with a lower efficiency. | CRISPR/Cas9-mediated genome editing. | Adapted from (52). | Patient-derived hiPSCs and genome-edited hESCs. Isogenic, mutation-corrected, hiPSCs were used as controls. | GATA6 homozygous mutations lead to impaired DE differentiation. Rescue of DE defects in these cells by re-expression of other GATA family members allows β-like cell production with a lower efficiency. hiPSCs with GATA6 heterozygous mutations show defects in DE differentiation. β-like cells produced in both cases are defective in the GSIS and in insulin processing. | (114) |
|              |                                      |                            |                         | Genomic editing hESCs (H1 and HUES8).                          |                               | Differentiation of GATA6+/− hiPSCs revealed impaired DE commitment and pancreatic endocrine differentiation. No defects in DE differentiation from GATA6+/− hiPSCs, but a lower number of PDX1+/− hESCs. No pancreatic progenitors and β-like cells was produced. GATA6 heterozygous hiPSCs present a modest decrease in the generation of DE, which differentiate less efficiently into MPCs and EPs. GATA6-null hiPSCs fail to enter the DE lineage. | (115) |
| **TALENs**   |                                      |                            |                         | Genomic editing hESCs (H9) |                               |                               | (53), adapted from (52). |
| **CRISPR-CAS9** |                                      |                            |                         | Adapted from (61, 62, 54). | hiPSCs derived from pancreatic agenesis patients with GATA6 heterozygous mutations. | hiPSCs derived from a patient with pancreatic agenesis. Isogenic, mutation-corrected hiPSCs were used as control. | (61, 62, 111), with some modifications. |
|              |                                      |                            |                         | Genomic editing hESCs (HUES8). |                               | hiPSCs with GATA6 heterozygous mutations present reduced efficiency for generation of pancreatic progenitor cells in vitro. Correction of these mutations allowed identifying a non-coding SNP that additionally contributes to the phenotype observed. | Adapted from (61, 62, 54). |
| **PDX1**     | Homozygous mutations in PDX1 result in pancreatic agenesis. PDX1 heterozygous patients exhibit diabetes caused by defects in β cell function and/or the maintenance of β cell mass in adults. Homozygous mutations in Pdx1 cause pancreatic agenesis, while heterozygous animals develop a pancreas but become diabetic in adulthood due to β cell apoptosis. | Homozygous mutations present a 65% reduction of INS+ cells at the β-like cell stage, which are mainly polyhormonal cells using the protocol described in this study. | TALEN and CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). |                                | (111) |

(Continued)
| Gene studied | Pancreatic defects reported in humans | Effects recapitulated in mice | Genome editing approach | Differentiation protocol | Type of human pluripotent stem cell | In vitro phenotypes | Ref. |
|--------------|-------------------------------------|-----------------------------|------------------------|-------------------------|----------------------------------|-------------------|-----|
| **RFX6**    | Patients carrying biallelic RFX6 inactivating mutations present a reduction in the pancreas size and obstruction of the small intestine. These patients present defects in the formation of pancreatic progenitors and their further differentiation into functional endocrine cells. | Similar to humans, Rfx6-null mice show variable degrees of pancreatic hypoplasia and premature death. | TALEN ad CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). | Differentiation of RFX6<sup>−/−</sup> mutant hESCs show a reduction in the number of PDX1<sup>+</sup> pancreatic progenitor cells. Severe reduction in β-like cells and complete absence of α cells. | (111) |
| **PTF1A**   | Homozygous inactivating mutations in PTF1A cause pancreatic and cerebellar agenesis. | Ptf1a-null mice present a complete absence of exocrine pancreatic tissue, but all islet endocrine cell types are present until the late stages of embryogenesis. | TALEN ad CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). | hPSCs with RFX6 homozygous mutations show normal DE and PFG differentiation, but fail to robustly activate PDX1. MPCs and endocrine-competent progenitors differentiate less efficiently from these cells. | (118) |
| **GLIS3**   | Biallelic mutations of GLIS3 underlie a rare clinical syndrome, characterized by neonatal diabetes and congenital hypothyroidism. | Global Glis3<sup>−/−</sup> mice die of severe neonatal diabetes shortly after birth. Minor differences in gene dosage of Glis3 produce substantive changes in the expression levels of Ngn3 and Ins1, leading to a variable phenotype among the multiple Glis3-KO mouse lines. | TALEN ad CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). | Differentiation of GLIS3<sup>−/−</sup> mutant hESCs do not present defects in pancreatic endocrine differentiation using the protocol described. | (111) |

CRISPR/Cas9-mediated genome editing.

Adapted from (62)

hipSCs were derived from patients with MRS and from their healthy, heterozygous father. hESCs (H9) was used as control.

CRISPR/Cas9-mediated genome editing.

Adapted from (64)

Genome-edited hESCs.

Differentiation of GLIS3<sup>−/−</sup> mutant hESCs show impaired expression of pancreatic endocrine-associated genes, including PDX1, NEUROD1, NKX6.1, and MAFA, and present increased β-like cell death. A chemical screen identified a drug candidate that rescues mutant GLIS3-associated β-cell death both in vitro and in vivo. | (64) | (Continued) |
TABLE 2 | Continued

| Gene studied | Pancreatic defects reported in humans | Effects recapitulated in mice | Genome editing approach | Differentiation protocol | Type of human pluripotent stem cell | In vitro phenotypes | Ref. |
|--------------|-------------------------------------|-----------------------------|------------------------|-------------------------|-----------------------------------|---------------------|-----|
| MNX1         | Homozygous mutations in MNX1 are associated with the occurrence of diabetes in infancy without evidence of exocrine pancreatic dysfunction. Reduced number of pancreatic endocrine cells, including β cells. | Mnx1-deficient mice show pancreatic duct-lobule agenesis and smaller pancreatic islets, while Mnx1 gain-of-function in the pancreas leads to aberrant pancreatic development. | TALEN ad CRISPR/Cas9. | Adapted from (52, 54). | Genome-edited hESCs (HUES8). | Differentiation of MNX1−/− mutant hESCs do not present defects in pancreatic endocrine differentiation using the protocol described. | (111) |

More recently, Lickert and colleagues generated hiPSCs from two patients with heterozygous missense mutations in the PDX1 coding region (PDX1C18R/+ and PDX1P33T/+), leading to single amino acid exchanges in its transactivation domain (112). By comparing with a control hiPSC line derived from a healthy donor, the authors showed that MPC differentiation was not affected in patient-derived hiPSCs. However, the PDX1 heterozygous point mutations impaired the differentiation of β-like cells and affected their response to glucose. A more severe effect was observed when artificially introducing the same point mutations in homozygosis (i.e. PDX1P33T/P33T and PDX1C18R/C18R) in isogenic cell lines derived from the original control cell. Interestingly, this resulted in impaired NKX6.1 induction in MPCs just in one of the cell lines (PDX1P33T/P33T). Nevertheless, when differentiated towards insulin producing cells, both homozygous cell lines yielded a decreased number of β-like cells with impaired glucose response. The authors also generated additional isogenic lines carrying different heterozygous mutations in the PDX1 transactivation domain, to generate a frame-shift mutation (PDX1+/−). This created a more severe phenotype to the one observed in the patient-derived hiPSCs, leading to similar outcomes as obtained from the homozygous isogenic PDX1P33T/P33T point mutated cells. Further transcriptomic analyses of MPCs differentiated from these cell lines ascribed the observed effects to downregulation of key PDX1-bound genes including MEG3 and NNA, which are involved in pancreas development and insulin secretion.

Taken together, these results illustrate how predisposition to develop diabetes can be provoked at the stage of pancreatic endocrine lineage development by genetic mutations on a gene that plays a key role at this timepoint. These anomalies could impair the glucose-responsive function of β-like cells through misregulation of genes involved in β cell development, maturation, and function. These results also emphasize that the choice between patient-derived hiPSCs or healthy donor hiPSCs with mutations artificially introduced, as well as the choice of the control cell line used, can affect experimental outcomes and their interpretations. In this context, patient-derived hiPSCs could carry additional mutations in non-coding regulatory regions and/or other genes which might further impair the in vitro differentiation outcomes. This effects have been elegantly exposed in a recent work by Gadue and colleagues (117), which will be discussed in more detail below, in the GATA6 section of this review. In contrast, the use of healthy donor hiPSCs with mutations artificially introduced has the advantage of enabling the use of isogenic cell lines (i.e. non-mutated hiPSCs) to exclude additional effects of the genetic background.

**RFX6**

Lack of Rfx6 in mice blocks differentiation of all islet cell types, with the exception of pancreatic-polypeptide-producing cells, while RFX6 mutations in humans result in PNDM (93, 100, 128). Modeling of the RFX6 requirement for human endocrine pancreas development has been addressed by Zhu et al. Their findings, in agreement with current knowledge, show a reduction of endocrine cell commitment from pancreatic progenitor cells derived from RFX6+/− mutant hPSCs (111).

In a more recent study, Trott et al. used hiPSCs derived from individuals with Mitchell–Riley syndrome (MRS) to specifically associate the role of RFX6 mutations and the lack of pancreatic endocrine cells in a human model of pancreas development (118). X-ray microtomography of one of these patients confirmed the spectrum of congenital defects typical of MRS (loss of the pancreas body and tail), and exome sequencing identified a homozygous non-sense mutation in RFX6. hiPSCs derived from this patient and differentiated along the pancreatic cell lineage revealed that these cells efficiently differentiate into posterior foregut cells but exhibited a reduction in the pancreatic endoderm differentiation, which was accompanied by expression of genes associated with mesoderm differentiation. These findings indicate that RFX6 is crucial for maintaining the transcriptional program that specifies early pancreatic endoderm in humans.
NEUROG3
While loss of Ngn3 function has been associated with complete lack of pancreatic endocrine cells in mice (129), the phenotype in humans is variable (recently reviewed in [21]). In this sense, while some patients with homozygous or compound heterozygous NEUROG3 mutations show glycemic control into adulthood, indicating a functional endocrine pancreas, others present neonatal diabetes (96, 130, 131). A recent study suggests that each mutation could have unique effects on the structure and function of NGN3 (132). To further understand this divergence, the requirement of NGN3 for the generation of insulin-producing cells during human development has been addressed using hPSC differentiation. Zhu et al. reported that in vitro endocrine pancreatic differentiation of hPSCs with biallelic mutations in NEUROG3 formed some insulin-producing cells (111), whereas another study reported a total lack of endocrine cells differentiated from NEUROG3+/− hPSCs (133). The latter work described that as little as 10% NEUROG3 expression is sufficient for the formation of pancreatic endocrine cells, supporting that NGN3 is essential for endocrine pancreas development in humans. The divergence between differentiation protocols used in each laboratory and the influence of genetic background could explain the varied phenotypes observed between these two studies. Interestingly, a new adult mouse islet resident pancreatic endocrine progenitor cell population has been recently reported (134). These cells express the surface marker Procr, are Neurog3 negative and, when isolated and co-cultured with endothelial cells, are able to give rise to islet-like clusters containing all endocrine cell types. Apparently, differentiation of this adult progenitor cell population into endocrine cells does not involve Neurog3 expression, raising the intriguing question of whether such a population exists in humans and, if so, whether in vitro pancreatic differentiation from hPSCs is able to follow this "alternative" path for endocrine cell production. Such possibility could explain the divergence between different reports concerning the requirement of NGN3 in endocrine cell production. Taken together, these studies illustrate the complexity, as well as the potential, associated with hPSC differentiation for modeling the impact of genetic mutations on human development.

GLIS3
It has been reported that global Glis3−/− mice die of severe neonatal diabetes shortly after birth (135). Minor differences in gene dosage of Glis3 produce substantive changes in the expression levels of Neurog3 and Ins1, leading to a variable phenotype among the multiple Glis3-KO mouse lines (136). In agreement with these phenotypes, human biallelic mutations in GLIS3 underlie a rare clinical syndrome, characterized by neonatal diabetes and congenital hypothyroidism (92).

The first report of the in vitro modeling for the requirement of GLIS3 in human pancreas development was provided by Zhu et al. These researchers did not find defects in pancreatic endocrine differentiation using GLIS3+/− mutant hESCs, when using a first generation in vitro pancreatic differentiation protocol that allows producing poly-hormonal cells (111).

More recently, Amin et al. developed an improved differentiation protocol that allowed the production of monohormonal β-like cells with enhanced functionality (64). Noteworthy, this protocol allowed the generation of robust GLIS3 expression at the PDX1+/NKX6.1+ pancreatic progenitor cell stage, in contrast with previously reported protocols (52, 111). Using this improved protocol, they were able to demonstrate that differentiation of GLIS3+/− mutant hESCs presented impaired expression of pancreatic endocrine-associated genes, including PDX1, NEUROD1, NKX6.1, and MAFA. These cells also showed increased β-like cell death. These findings contrast with those reported by Zhu et al. (111). The difference could be explained by the improvements in the differentiation protocol, which allow a closer recapitulation of the differentiation steps to produce β-like cells. Furthermore, providing an illustrative example of the utility of the in vitro β cell differentiation protocols, these researchers performed a chemical screen that allowed the identification of a novel drug candidate that rescued mutant GLIS3-associated β-cell death both in vitro and in vivo (64).

HNF1A
Hnf1a has been shown to regulate the expression pattern of islet-specific genes involved in key functions of this tissue (137). In the mouse, while homozygous knockout (Hnf1a−/−) results in insulin secretory defects and higher blood glucose concentrations, heterozygous knockout (Hnf1a+/−) do not display this phenotype (138). This is in sharp contrast with the MODY3 pathology in humans, in which heterozygous mutations result in diabetes (139). In an attempt to elucidate the mechanisms by which dysfunctional HNF1A affects pancreatic development and/or β cell function, Gadue and colleagues have modeled MODY3 using CRISPR-Cas9 genome-edited hESCs and EndoC-BH human cell lines (109). Loss of HNF1A function was accomplished by deletion and premature termination in one or both HNF1A alleles, resulting in heterozygous and homozygous KO mutations. Their results suggest that HNF1A plays an essential role in endocrine cell development, as its loss leads to abnormal expression of genes related to β cell function and diabetes. Noteworthy, complete loss of HNF1A did not impair the production of pancreatic progenitors, but this factor was necessary for proper endocrine cell development as revealed by decreased expression of PAX4, and impaired insulin expression and secretion. Interestingly, HNF1A loss of function (deletion in one or both alleles of HNF1A) led to increased expression of α cell markers, including glucagon. The authors suggest that the increase found in α cells derived from this model system appears to be human-specific, since Hnf1a knockout mice do not display this phenotype.

Another key finding of this work was the identification of a previously unannotated human-specific long intergenic non-coding RNA (lncRNA). The LINC01139, designated LINKA, was shown to act as a downstream target of HNF1A. In vitro endocrine pancreatic differentiation of LINKA-deficient hESCs showed no effect on the production of pancreatic progenitors, but revealed a limited bias towards the production of α cells. Furthermore, β-like cells produced from LINKA-deficient hESCs showed a decrease in maximal respiration capacity to a similar extent as seen in the HNF1A heterozygous cells. Taken together, their findings point to a role for LINKA in the regulation of α-cell development.
subset of HNF1A target genes with implications in cellular respiration. The *in vivo* relevance of *LINKA* for diabetes onset remains to be explored. Of note, a significant variability was observed in the expression changes among the hESC lines used in this study. These could be partially explained by the impact of the genetic background, which could lead to differences in the efficiency of differentiation protocol when applied to each cell line.

A more recent report was provided by Teo and colleagues (110). These researchers used MODY3 patient-derived hiPSCs to study the impact of a recently reported patient-specific heterozygous HNF1A<sup>+/H126D</sup> mutation (140). The authors used hiPSCs reprogrammed from a healthy donor and H9 hESCs as two independent wild type controls. Molecular dynamics simulations predicted that the H126D mutation could compromise DNA binding and gene target transcription. Indeed, RNA-seq and ChIP-seq analyses performed on MODY3 hiPSC-derived endocrine progenitors revealed that the expression of several HNF1A gene targets was affected by the mutation. An in-depth analysis of the effects on the β-like cells derived from HNF1A<sup>+/H126D</sup> hiPSCs demonstrated that the HNF1A mutation causes a GLUT2 deficiency, that is associated with reduced glucose uptake and ATP production. Their findings reveal the importance of HNF1A in regulating GLUT2 and several genes involved in the MODY3 pathology that may partly account for the lack of insulin secretion clinically observed in these patients. This report extends the findings reported by Cardenas-Diaz et al. (109) by revealing additional mechanisms triggered by the HNF1A mutations on the rest of the stimulus-secretion coupling pathway and on HNF1A transcriptional targets in human β-like cells. Noteworthy, Teo and colleagues performed RNA-seq and ChIP-seq at the endocrine progenitor cell stage. They did not find a differential regulation of the *LINKA* (LINKA) at this stage, and unfortunately the expression of this IncRNA in β-like cells derived from HNF1A<sup>+/H126D</sup> hiPSCs is not reported. It remains to be elucidated whether *LINKA* is also downregulated in the latter model. Potential discrepancies on the regulation of this IncRNA could be accounted by the different approaches followed in each work to evaluate the effects of HNF1A haploinsufficiency. On one hand Cardenas-Diaz et al. artificially introduced KO mutations by generating a genomic deletion leading to premature termination in one or both HNF1A alleles, and non-mutated isogenic cell lines were used as controls. This approach has the advantage of using an isogenic control cell line, which neutralizes contributions from the genomic background. However, the mutations introduced generate a strong HNF1A loss of function that might not appropriately recapitulate the mechanisms that take place in MODY3 patients. On the other hand, Teo and colleagues used MODY3 patient-derived hiPSCs carrying a mutation that causes an amino acid substitution (HNF1A<sup>+/H126D</sup>) and used hiPSCs derived from a healthy donor and H9 hESCs as wild type controls. This approach has the advantage of using hiPSCs derived from patient cells, accounting for a closer model to the MODY3 disease. However, the use of non-isogenic hiPSCs as controls does not allow accounting for potential effects derived from the different genomic backgrounds. As presented in more detail in the next section, these might introduce an additional bias in the differentiation outcome. In summary, further studies are required to elucidate whether deregulation of *LINC01139* plays a relevant role in MODY3 diabetes.

**GATA 6**

Mono allelic mutations in GATA6 have been linked with pancreas agenesis in humans (141) while the knockout of the same gene has little effect on pancreatic development in the mouse. Indeed, only knockout of both *Gata6* and *Gata6b* results in pancreatic agenesis (142, 143). Thus, GATA6 seems to have a different or at least a more extensive function in human development. To confirm this observation, Shi et al. used CRISPR/Cas9 to create hiPSCs carrying frameshift mutations in GATA6, alone or in combination with GATA4 mutations (115). Their results show that GATA6<sup>−/−</sup> haploinsufficiency alters pancreatic progenitor cell differentiation leading to a reduced number of glucose-responsive β-like cells. Given that heterozygous inactivating mutations in GATA6 have been linked with pancreas agenesis, these findings suggest that the severity of the phenotype could vary according to additional genetic, epigenetic, and/or environmental factors that were not accounted by the differentiation process. Interestingly, the authors also describe dosage-sensitive requirements for GATA6 and GATA4 in the formation of both definitive endoderm and pancreatic progenitor cells, confirming the complex interplays between these factors observed in genetic studies in the mouse.

In another study, Tiyaboonchai et al. used hiPSCs derived from a patient with pancreatic agenesis associated with a heterozygous GATA6 frameshift mutation, which leads to production of a truncated protein. These researchers also used CRISPR/Cas9 genome editing to introduce this mutation on both alleles of the same hiPSC line (114). Noteworthy, hiPSC lines with homozygous mutations failed to differentiate into endoderm. Re-expression of GATA6 or other GATA family members restored this defect. The use of endodermal progenitor cell lines established from the hiPSC allelic series, which expressed GATA6 at lower levels but GATA4 and GATA3 at higher levels, allowed bypassing the endoderm defect and focusing on pancreatic β cell differentiation. The authors found that all mutant lines were able to differentiate into pancreatic β-like cells, but the response to glucose in these cells was functionally defective. Also, they showed that the clear decrease in pancreas specification and β-like cell generation was associated with limited endogenous retinoic acid signaling during *in vitro* pancreas induction using the GATA6 mutant cell lines.

Additional information was provided by Chia et al. who combined both gene-edited and patient-derived hPSCs to study the function of GATA6 (116). These authors found that GATA6 heterozygous hPSCs show a limited reduction in endoderm formation, while GATA6-null hPSCs can only form mesoderm-like cells. Thus, GATA6 seems to be upstream of the
endoderm program in humans. Consistent with this hypothesis, genome-wide studies showed that GATA6 binds and cooperates with EOMES/SMAD2/3 to regulate the expression of master endoderm genes. In addition, the early deficit of GATA6\(^{iv/v}\) in definitive endoderm was accompanied by a significant reduction in PDx1+ pancreatic progenitors and C-peptide+ \(\beta\)-like cells. These findings show that, in humans, the formation of definitive endoderm and acquisition of pancreatic fate are exquisitely sensitive to GATA6 gene dosage.

Taken together, the above-mentioned reports revealed different levels of requirement of GATA6 for pancreatic differentiation between protocols, labs and cell lines (Table 2). In this context, a very recent report by Gadue and colleagues provides an illustrative example which might help to understand this apparent divergence. These researchers generated a hiPSC line derived from a pancreatic agenesis patient, harboring a heterozygous 4 bp duplication in exon 2 of GATA6 leading to a premature STOP codon, a genetically matched control line, and an identically artificially-mutated ESC line. Using these cell lines, the authors identified a minor allele frequency of a SNP located downstream of GATA6 which was associated with the level of expression of this gene (117). In their in vitro model, the expression of the GATA6 protein remained depressed in pancreatic progenitor cells even after correction of the coding mutation. Screening the regulatory regions of the GATA6 gene in the patient cells and an additional pancreas agenesis hiPSC line revealed the above-mentioned SNP. Noteworthy, introducing this non-coding disease modifier SNP by CRISPR/Cas9 in control hESCs confirmed that it depressed GATA6 expression in pancreas precursors. Thus, the phenotypic diversity found in GATA6 heterozygous patients and the outcome of in vitro studies could be explained in part by this genetic variant.

The findings reported by Gadue and colleagues suggest that caution has to be taken when interpreting the results of monogenic diabetes modeling using patient-derived hiPSCs. Additional genomic variants might contribute to the in vitro differentiation outcomes, making it difficult to compare the results obtained by different groups. Nevertheless, some of the studies mentioned above did use the same hiPSC line, including the original H9 line derived by JA Thomson and colleagues (144). In such cases, it is worth to underline that each group used different protocols of differentiation. Specific additives could compensate for the decrease in GATA6 expression. For example, retinoic acid seems to support GATA6 function in pancreatic specification. Addition/increase of this morphogen could modulate the effect of GATA6 haploinsufficiency. Taken together, these results illustrate the challenges and, at the same time, highlight the unique interest of investigating the function of key transcription factors in pancreatic development using hPSCs.

HNF4A

In mouse, it has been shown that full inactivation Hnf4a is embryonically lethal, while heterozygote knockout mice are normoglycemic and do not present diabetes features (145–147). In contrast, MODY1 patients carrying heterozygous mutations in HNF4A present diabetes due to impaired \(\beta\) cell function (148). Patient-derived hiPSCs have been recently used to address the potential mechanisms involved in this phenotype. Ræder and colleagues reported the use of hiPSCs derived from patients carrying a non-sense HNF4A mutation associated with MODY1 to study its effect on pancreas and \(\beta\) cell differentiation (105). Noteworthy, the mutation studied in this work (p. Ile271fs) generates a truncated HNF4A product from one of the alleles. The authors show that insulin-positive cells could be generated in vitro from these cells, suggesting that this human HNF4A mutation neither blocked the expression of the insulin gene nor the production of insulin-producing cells in vitro. However, they acknowledge that the insulin-producing cells derived are immature as a result of the \(\beta\) cell differentiation protocol per se, leaving open the possibility that HNF4A could have more subtle effects on the functionality of fully mature \(\beta\) cells.

In another study, Braverman-Gross et al. generated hiPSCs from MODY1 patients harboring a different non-sense mutation in the HNF4A gene and evaluated its differentiation along the pancreatic lineage (106). In this case, the mutation studied affects all HNF4A transcripts and impairs the protein dimerization and transactivation domains. Pancreatic progenitors differentiated from these cells exhibited an upregulation of other key pancreatic transcription factors, including PAX6, NEUROD1, and NEUROG3. The authors suggest that such gene expression increase could be a compensatory mechanism utilized by MODY1 cells to overcome the reduction in HNF4A expression. Interestingly, they also note that the differential expression of HNF4A target genes in posterior foregut progenitors derived from mutant cells is affected by the number of HNF4A DNA binding sites, its transcription start site distance, and the number of other transcription factor binding sites. Unfortunately, the authors of this work did not extend the differentiation protocol to evaluate proportion and functionality of \(\beta\)-like cells derived from these hiPSC samples.

MODY1 disease modeling was also more recently accomplished by Teo and colleagues using hiPSCs derived from patients with frameshift mutations that introduce a premature stop codon in HNF4A, leading to an unstable mRNA and overall lowered HNF4A levels (107). This mutation is the same one (p. Ile271fs) studied by Ræder and colleagues. Control hiPSC lines were derived from a non-diabetic patient family member. The resulting cell lines were differentiated into liver and pancreatic endocrine cells. Phenotypic analyses showed that HNF4A haploinsufficiency affects foregut endoderm gene expression signatures, contributing to long-term consequences on hepatic and pancreatic cell fates. While key developmental genes were perturbed by HNF4A haploinsufficiency at the pancreatic progenitor stage (including HNF1B, PDx1, GATA4, and RFX6), these mutant hiPSCs were still able to procure \(\beta\)-like cells expressing specific markers, including insulin and C-peptide. However, the \(\beta\)-like cells derived with the assayed in vitro protocol were not fully mature. More critical effects of HNF4A mutations taking place during the \(\beta\) cell maturation process or on already mature \(\beta\) cells could not be properly evaluated with the protocol described in this work.
Taken together, the results reported so far from hiPSC models used to study the effects of different HNF4A mutations suggest that the effects of such mutations might be more relevant at the functional level of the β cells produced. The generation of fully functional β-like cells from in vitro differentiation protocols still remains a challenge. Thus, evaluating the functionality of the β-like cells produced from control or patient-derived hiPSC cannot be appropriately assessed with the current differentiation protocols. On the other hand, it should be noted that while two of these studies evaluated the effects of the same mutation, the results described by Braverman-Gross et al. analyzed a different HNF4A mutation. These mutations lead to HNF4A loss-of-function through different mechanisms, thus potentially explaining the different outcomes obtained in each of the reports. Last, but not least, it should be kept in mind when using patient-derived hiPSCs that additional mutations in other genes or in HNF4A regulatory regions could also modulate the outcome of the in vitro differentiation experiments, as illustrated above for GATA6. To conclude, additional studies are necessary to address how HNF4A mutations cause MODY in humans, especially using the next generation of pancreatic differentiation protocols that improve the production of fully mature β-like cells.

**HNF1B**

Teo and colleagues established a well-controlled patient-derived hiPSC pancreatic differentiation model to elucidate the molecular mechanisms underlying MODY5 pancreatic hypoplasia (113). Differentiation of MODY5-hiPSCs into pancreatic progenitors showed that the HNF1B<sup>14delT</sup> mutation causes the up-regulation of several key endocrine pancreas-enriched transcription factors including PDX1. Pancreatic differentiation using these cells did not block PDX1, PTF1A, GATA4, and GATA6 expression, suggesting that MODY5-mediated pancreatic hypoplasia in this case is mechanistically independent from the effect associated with these transcription factors. On the other hand, the point mutation in HNF1B caused an indirect reduction in the expression of the insulin gene activator PAX6, suggesting that loss of one copy of HNF1B in humans impairs β-cell development and function. Although these findings are consistent with the potential occurrence of maturity-onset diabetes, they fail to uncover the mechanism by which HNF1B haploinsufficiency results in pancreatic hypoplasia.

To further address this question, we recently used an alternative hiPSC pancreatic differentiation model to elucidate the molecular mechanisms underlying HNF1B-associated diabetes (Khairi et al, manuscript submitted). To evaluate the transcriptional differences in the HNF1B haploinsufficient cells, we used bulk RNA-seq at several stages of the pancreatic differentiation protocol (from DE to β-like cells), immunofluorescence staining, and scRNA-seq at the MPC stage. Our analyses show that absence of HNF1B blocks the specification of the pancreatic fate from the foregut progenitor stage. In contrast, HNF1B haploinsufficiency allows differentiation of MPCs and the generation of functional β-like cells although at a lower frequency than the control isogenic cell line. We further report that HNF1B haploinsufficiency impairs cell proliferation in foregut progenitors and MPCs. Our results show that HNF1B plays a key role in the production and expansion of pancreatic progenitors and suggest that this factor could regulate the expression of several Hippo pathway components in MPCs. Thus, the level of HNF1B, combined with environmental stimuli, could define the number of pancreatic progenitor cells generated during development and therefore contribute to the susceptibility to diabetes during childhood/adulthood.

**PTF1A**

It has been described that homozygous inactivating mutations in PTF1A cause pancreatic and cerebellar agenesis (98). In agreement, Ptf1a null mice present a complete absence of exocrine pancreatic tissue, but all islet endocrine cell types are present until the late stages of embryogenesis (149). Zhu et al. reported the in vitro modeling of the PTF1A requirement for human pancreas development. Using PTF1A<sup>−/−</sup> hESCs and a first generation in vitro pancreatic differentiation protocol, these researchers did not find defects in pancreatic endocrine differentiation (111). This finding is in agreement with previous reports showing that Ptf1a is not required for the specification of Ngn3+ endocrine progenitors or the differentiation of mature β cells in mice (150).

The study of PTF1A regulation provides another example of how human in vitro pancreatic differentiation can guide the discovery of a developmental regulatory mechanism, in this case consisting in the identification of recessive mutations in a distal non-coding region (151). Identification of genetic mutations resulting in pancreatic agenesis can be challenging as these can be located in regulatory regions far away from known regulators. Accordingly, genome sequencing of a cohort of patients presenting pancreatic agenesis revealed several mutations in a distal non-coding region located >1 Mb upstream the PTF1A gene. Enhancer profiling in MPCs, derived in vitro from hPSCs, confirmed the functional importance of this regulatory sequence in humans (151). The mutation sites coincided with a FOXA2 binding site profiled by ChIP-seq in in vitro MPCs. Further mechanistic experiments performed in vitro confirmed that the targeted region acts as an enhancer in human MPCs, and that patient mutations affect PDX1 and FOXA2 binding. These findings allowed us to propose that the mutated enhancer region is in charge of triggering the early PTF1A expression in the gut region where the pancreas is specified. This study illustrates how human genetic and in vitro differentiation of hPSCs can be combined to define mechanisms driving developmental diseases.

**INS**

Balboa et al. generated a model based on hiPSCs from patients carrying INS mutations and engineered isogenic CRISPR-Cas9 mutation-corrected lines. These cells were differentiated to β-like cells (152). Using this model, the authors show that the INS mutations lead to accumulation of proinsulin misfolding, increased signs of ER-stress, and reduced proliferation in INS-mutant β-like cells compared with corrected controls. Following transplantation into mice, INS-mutant grafts presented reduced insulin secretion and further increased ER-stress, associated with
decreased PDX1 expression and β cell size, as well as mitochondrial alterations. The authors conclude that neonatal diabetes-associated INS-mutations lead to defective β cell mass expansion, contributing to neonatal diabetes development.

In another recent study, Egli and colleagues generated hiPSCs from fibroblasts of a patient with PNDM and undetectable insulin at birth due to a homozygous mutation in the translation start site of the insulin gene (153). Their results show that the differentiation of INS mutant cells resulted in hormone-negative hiPSCs, and the correction of this mutation by CRISPR-Cas9 restored insulin production and secretion to levels comparable to those of wild type endocrine cells. The authors also demonstrate that the insulin-producing cells of corrected patient hiPSCs protect mice from diabetes, providing a proof-of-principle study for the use of replacement therapy as a treatment for monogenic diabetes.

**STAT3**
Saarimäki-Vire et al. used hiPSCs derived from a patient with PNDM and pancreatic hypoplasia to investigate the effects of an activating STAT3 mutation on pancreatic development (154). Noteworthy, the mutation studied has been identified as the cause of PNDM in association with early onset autoimmunity. These authors demonstrate that the mutation in STAT3 leads to premature endocrine differentiation through binding and direct induction of NEUROG3 by the increased nuclear shuttling of the mutated protein. They also showed that correction of the STAT3 mutation using CRISPR/Cas9 completely reversed the disease phenotype. These results demonstrate that, in addition to the early onset autoimmunity, the same mutation leads to a primary developmental defect in pancreatic organogenesis.

**CONCLUSION AND FUTURE DIRECTIONS**
The field of hPSCs has allowed important advances in our understanding of the molecular mechanisms underlying the different forms of monogenic diabetes. Indeed, the establishment of hPSC-based in vitro platforms offers a unique opportunity to study pancreas development and to investigate the pathophysiology underlying monogenic diabetes. This basic knowledge paves the way to the development of new treatments, not only for diabetes induced by genetic mutations, but also more broadly for personalized medicine therapies in the context of type I and type II diabetes. Nonetheless, several challenges require attention. Current in vitro β-like cell differentiation protocols have been markedly improved and may be sufficient to recapitulate several of the MODY phenotypes in the hPSC-based model. However, one of their greatest limitations remains the lack of metabolic maturation of the β-like cells derived. A solution to turn the differentiated cells into fully mature and functional β cells has been their transplantation in mouse to allow for the latest steps of cell differentiation to take place in vivo. Alternative methods involve culture in 3D and cell self-aggregation into islet-like clusters to produce β-like cells with improved functionality. The emergence of scRNA-seq is expected to lead to the identification of new markers involved in pancreatic β cell maturation, thus allowing improved benchmarking of the in vitro differentiation protocol outcomes. Also, scRNA-seq applied to human embryonic pancreatic tissue might provide additional insights into the developmental cues that differ among mice and humans. This will provide additional input to improve the in vitro differentiation protocols by modulating yet unknown signaling cues.

The other growing challenge is the divergence of results between different groups studying the same mutation/genes but using either different hPSC lines and/or different protocols. Indeed, genetic background and culture conditions can have a strong effect on phenotype, thus leading to different experimental outcomes. New hiPSC lines derived from monogenic diabetic patients continue to be reported. A very recent study described the generation of hiPSCs derived from MODY2 patients, but in this case its differentiation into the pancreatic lineage was not evaluated so far (108). Thus, there is a need to develop standard hiPSC lines which could be shared between laboratories. More importantly, the use of “universal” culture conditions to grow and to differentiate hPSC lines would be incredibly useful to allow the comparison of data generated and to precisely establish the importance of genetic background on the phenotype observed in vitro. Such standardization implies that culture conditions are fully described and shared between laboratories. The use of isogenic control hPSC lines is also essential and is helping to overcome the limitations related to the variability between lines, especially when compared with the use of family controls, which is inherent to differences in genetic background. Numerous studies have successfully used CRISPR/Cas9 tools to generate isogenic hPSC lines by introducing patient-specific mutations, editing genes in control-hPSC lines to investigate the implication of a single genetic variant on β cell differentiation and function. Here, we revisited the latest advances in the application of in vitro pancreatic cell differentiation from hPSCs to model several types of monogenic diabetes. Much work remains to be done to improve the modeling of monogenic diabetes but, as it stems from this review, in vitro pancreatic differentiation from hPSCs is definitely gaining momentum.

**AUTHOR CONTRIBUTIONS**
All authors reviewed the literature, wrote, and edited the paper. JIB prepared the table. LV and SAR-S conceptualized the review topic and contents, and approved the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**
This work was funded by Office of the Royal Society and the Consejo Nacional de Investigaciones Científicas y Técnicas of Argentina (IEC/R2\181023 to SAR-S and LV). Work in the Rodríguez-Seguí laboratory is supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica of Argentina (ANPCyT: PICT-2015 3605, PICT-2017 2071) and
ACKNOWLEDGMENTS

We apologize to our colleagues whose references were omitted owing to space constraints. SAR-S is a career investigator from the Consejo Nacional de Investigaciones Científicas y Técnicas of Argentina (CONICET). JIB is supported by a postdoctoral fellowship from the ANPCyT.
Burgos et al. Monogenic Diabetes Modeling Using hPSCs

91. Firdous P, Nissar K, Ali S, Ganai BA, Shabir U, Hassan T, et al. Genetic
92. Senee V, Chelala C, Duchatelet S, Feng D, Blanc H, Cossec JC, et al. Mutations in GLIS3 Are Responsible for a Rare Syndrome With Neonatal Diabetes Mellitus and Congenital Hypothyroidism. *Nat Genet* (2006) 38:682–7. doi: 10.1038/ng1802
93. Carr ropes, Qui HR, Taleb N, Kishimoto NY, Schee DW, Lu Y, et al. Rfx6 Directs Isl1 Formation and Insulin Production in Mice and Humans. *Nature* (2010) 463:775–80. doi: 10.1038/nature08748
94. Flanagan SE, De Franco E, Lango Allen H, Zerah M, Abdul-Rasoul MM, Edge JA, et al. Analysis of Transcription Factors Key for Mouse Pancreatic Development Establishes Nkx2-2 and MNX1 Mutations as Causes of Neonatal Diabetes in Man. *Cell Metab* (2014) 19:146–54. doi: 10.1016/j.cmet.2013.11.021
95. Bonnefond A, Vaillant E, Philippe J, Skrobek B, Lobbens S, Vengo L, et al. The Transcription Factor Gene MNX1 Is a Novel Cause of Permanent Neonatal Diabetes in a Consanguineous Family. *Diabetes Metab* (2013) 39:276–80. doi: 10.1016/j.diabet.2013.02.007
96. Rubio-Cabezas O, Jensen JD, Hodgson MJ, Coder E, Eillard S, Serup P, et al. Permanent Neonatal Diabetes and Enteric Anadencrosis Associated With Biallelic Mutations in NEUROG3. *Diabetes* (2011) 60:1349. doi: 10.2337/db10-1008
97. Rubio-Cabezas O, Minton JAL, Kantor I, Williams D, Eillard S, Hattersley AT. Homozygous Mutations in NEUROD1 Are Responsible for a Novel Syndrome of Permanent Neonatal Diabetes and Neurological Abnormalities. *Diabetes* (2010) 59:2326. doi: 10.2337/db10-0011
98. Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, J Coleman R, Garrett C, et al. Mutations in Ptf1a Cause Pancreatic and Cerbellar Agnesis. *Nat Genet* (2004) 36:1301–5. doi: 10.1038/ng1475
99. Dimitri P, Warner JT, Minton JA, Patch AM, Eillard S, Hattersley AT, et al. Novel GLIS3 Mutations Demonstrate an Extended Multisystem Phenotype. *Eur J Endocrinol* (2011) 164:437–43. doi: 10.1530/EJE-10-0893
100. Concepcion JP, Reh CS, Daniels M, Liu X, Paz VP, Ye H, et al. Neonatal Diabetes, Gallbladder Agenesia, Duodenal Atresia, and Intestinal Malrotation Caused by a Novel Homozygous Mutation in RFX6. *Pediatr Diabetes* (2014) 15:67–72. doi: 10.1111/pedi.12063
101. Rieck S, Bankaitis ED, Wright CV. Lineage Determinants in Early Endocrine Differentiation. *Semin Cell Dev Biol* (2010) 21:673–84. doi: 10.1016/j.semcdb.2010.06.005
102. Clissold RL, Hamilton AJ, Hattersley AT, Eillard S, Bingham C. HNF1B-Associated Renal and Extra-Renal Disease- an Expanding Clinical Spectrum. *Nat Rev Nephrol* (2011) 7:102–12. doi: 10.1038/nrneph.2014.232
103. Edghill EL, Bingham C, Slingerland AS, Minton JA, Noordam C, Eillard S, et al. Hepatocyte Nuclear Factor-1 Beta Mutations Cause Neonatal Diabetes and Intrauterine Growth Retardation: Support for a Critical Role of HNF-1beta in Human Pancreatic Development. *Diabetes Med* (2006) 23:1301–6. doi: 10.1111/j.1464-5491.2006.01993.x
104. Bellanne-Chantelot C, Clauin S, Chauveau D, Collin P, Daumont M, Douillard C, et al. Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-Ibeta (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of the Young Type S. *Diabetes* (2005) 54:3126–32. doi: 10.2337/diabetes.54.11.3126
105. Vethe H, Björljyke Y, Ghila LM, Paolo JA, Scholtz H, Gygi SP, et al. Probing the Mature β Cell Proteomic Landscape in Differentiating Patient-Idsc-Derived Cells. *Sci Rep* (2017) 7:4780. doi: 10.1038/s41598-017-04979-w
106. Braverman-Cross C, Nudel N, Ronen D, Beer NL, McCarthy MI, Benvenisty N. Derivation and Molecular Characterization of Pancreatic Differentiated MODY1-Idscs. *Cell Stem Cell* (2018) 31:1004–1016.e5. doi: 10.1016/j.stem.2018.04.004
107. Hattersley AT, Turner RC, Patel P, O’Rahilly S, Wainscoat JS, Permutt MA, et al. Linkage of Type 2 Diabetes to the Glucokinase Gene. *Lancet* (1992) 339:1307–10. doi: 10.1016/0140-6736(92)91958-B
108. Fregou P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close Linkage of Glucokinase Locus on Chromosome 7p to Early-Onset non-Insulin-Dependent Diabetes Mellitus. *Nature* (1992) 356:162–4. doi: 10.1038/356162a0
109. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the Hepatocyte Nuclear Factor-1 Alpha Gene in Maturity-Onset Diabetes of the Young (MODY3). *Nature* (1996) 384:455–8. doi: 10.1038/384455a0
110. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, et al. Mutations in the Hepatocyte Nuclear Factor-4 Alpha Gene in Maturity-Onset Diabetes of the Young (MODY1). *Nature* (1996) 384:458–60. doi: 10.1038/384458a0
111. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, et al. Mutation in Hepatocyte Nuclear Factor-1 Beta Gene (TCF2) Associated With MODY. *Nat Genet* (1997) 17:384–5. doi: 10.1038/ng1927-384
112. Firdous P, Nissar K, Ali S, Ganai BA, Shahab U, Hassan T, et al. Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives. *Front Endocrinol* (2018) 9:923. doi: 10.3389/fendo.2018.00923
113. Senee V, Chelala C, Duchatelet S, Feng D, Blanc H, Cossec JC, et al. Mutations in GLIS3 Are Responsible for a Rare Syndrome With Neonatal Diabetes Mellitus and Congenital Hypothyroidism. *Nat Genet* (2006) 38:682–7. doi: 10.1038/ng1802
114. Carr ropes, Qui HR, Taleb N, Kishimoto NY, Schee DW, Lu Y, et al. Rfx6 Directs Isl1 Formation and Insulin Production in Mice and Humans. *Nature* (2010) 463:775–80. doi: 10.1038/nature08748
115. Flanagan SE, De Franco E, Lango Allen H, Zerah M, Abdul-Rasoul MM, Edge JA, et al. Analysis of Transcription Factors Key for Mouse Pancreatic Development Establishes Nkx2-2 and MNX1 Mutations as Causes of Neonatal Diabetes in Man. *Cell Metab* (2014) 19:146–54. doi: 10.1016/j.cmet.2013.11.021
116. Bonnefond A, Vaillant E, Philippe J, Skrobek B, Lobbens S, Vengo L, et al. The Transcription Factor Gene MNX1 Is a Novel Cause of Permanent Neonatal Diabetes in a Consanguineous Family. *Diabetes Metab* (2013) 39:276–80. doi: 10.1016/j.diabet.2013.02.007
117. Cardenas-Diaz FL, Osorio-Quintero C, Diaz-Miranda MA, Kishore S, Leavens K, Jobaliya C, et al. Modeling Monogenic Diabetes Using Human Escs Reveals Developmental and Metabolic Deficiencies Caused by Mutations in HNF1A. *Cell Stem Cell* (2019) 25:273–289.e5. doi: 10.1016/j.stem.2019.07.007

Frontiers in Endocrinology | www.frontiersin.org 17 July 2021 | Volume 12 | Article 692596
110. Low BSJ, Lim CS, Ding SSL, Tan YS, Ng NHJ, Krishnan VG, et al. Decreased GLUT2 and Glucose Uptake Contribute to Insulin Secretion Defects in MODY3/HNF1A Hipsc-Derived Mutant Cells. *Nat Commun* (2021) 12:3133. doi: 10.1038/s41467-021-22843-4

111. Zhu Z, Li QV, Lee K, Rosen BP, González F, Soh C-L, et al. Genome Editing of Lineage Determinants in Human Pluripotent Stem Cells Reveals Mechanisms of Pancreatic Development and Diabetes. *Cell Stem Cell* (2016) 18:755–68. doi: 10.1016/j.stem.2016.03.015

112. Wang X, Sterr M, Ansarullah, Burtscher I, Böttcher A, Beckenbauer J, et al. Early Chia CY, Madrigal P, Denil SLIJ, Martinez I, Garcia-Bernardo J, El-Khairi R, et al. Early Developmental Perturbations in a Human Stem Cell Model of MODY5/HNF1B Pancreatic Hypoplasia. *Stem Cell Rep* (2016) 6:357–67. doi: 10.1016/j.stem.2016.01.007

113. Tiyaaboobancha A, Cardenas-Diaz FL, Ying L, Maguire JA, Sim X, Jobalita C, et al. GATA6 Plays an Important Role in the Induction of Human Definitive Endoderm, Development of the Pancreas, and Functionality of Pancreatic β Cells. *Cell Stem Cell* (2017) 8:589–604. doi: 10.1016/j.stem.2016.12.026

114. Shih DQ, Heimesaat M, Kuwajima S, Stein R, Wright CVE, Stoffel M. Neurogenin 3 Is Important But Not Essential for Pancreatic Islet Development in Humans. *Diabetologia* (2014) 57:2421–4. doi: 10.1007/s00125-014-3349-y

115. Ellard S, Colclough K. Mutations in the Genes Encoding the Transcription Factors Hepatocyte Nuclear Factor 1 Alpha (HNF1A) and 4 Alpha (HNF4A) in Maturity-Onset Diabetes of the Young. *Hum Mutat* (2000) 17:138–69. doi: 10.1002/1098-1004(200002)17:2<138::AID-HUMU10>3.0.CO;2-0

116. Matsuoka Y, Hori T, Slusarski D, Kawamura K, Koiwa H, et al. Reduced PDX-1 Expression Impairs Islet Response to Insulin Resistance and Worsens Glucose Homeostasis. *Am J Physiol-Endocrinol Metab* (2005) 288: E707–14. doi: 10.1152/ajpendo.00325.2004

117. Brissova M, Shibata N, Hirota T, Fujimiya T, Kojima K, et al. Reduced Islet Apoptosis in Pdx1+/−/ Mice. *J Clin Invest* (2003) 111:1147–60. doi: 10.1172/JCI16537

118. Stoffels DA, Farrow J, Clarke WL, Habener JF. Early-Onset Type-II Diabetes Mellitus (MODY4) Linked to IF1. *Nat Genet* (1997) 17:138–9. doi: 10.1038/ng1097-138

119. Burgos et al. Monogenic Diabetes Modeling Using hPSCs

120. Wang X, Sterr M, Ansarullah, Burtscher I, Böttcher A, Beckenbauer J, et al. Point Mutations in the PDX1 Transactivation Domain Impair Human β-Cell Development and Function. *Mol Metab* (2019) 24:80–97. doi: 10.1016/j.molmet.2019.03.006

121. Teo AK, Lau HH, Valdez IA, Dirice E, Taer H, et al. Early Developmental Perturbations in a Human Stem Cell Model of MODY5/HNF1B Pancreatic Hypoplasia. *Stem Cell Rep* (2016) 6:357–67. doi: 10.1016/j.stem.2016.01.007

122. Shih DQ, Heimesaat M, Kuwajima S, Stein R, Wright CVE, Stoffel M. Neurogenin 3 Is Important But Not Essential for Pancreatic Islet Development in Humans. *Diabetologia* (2014) 57:2421–4. doi: 10.1007/s00125-014-3349-y

123. Ellard S, Colclough K. Mutations in the Genes Encoding the Transcription Factors Hepatocyte Nuclear Factor 1 Alpha (HNF1A) and 4 Alpha (HNF4A) in Maturity-Onset Diabetes of the Young. *Hum Mutat* (2000) 17:138–69. doi: 10.1002/1098-1004(200002)17:2<138::AID-HUMU10>3.0.CO;2-0

124. Matsuoka Y, Hori T, Slusarski D, Kawamura K, Koiwa H, et al. Reduced PDX-1 Expression Impairs Islet Response to Insulin Resistance and Worsens Glucose Homeostasis. *Am J Physiol-Endocrinol Metab* (2005) 288: E707–14. doi: 10.1152/ajpendo.00325.2004

125. Brissova M, Shibata N, Hirota T, Fujimiya T, Kojima K, et al. Reduced Islet Apoptosis in Pdx1+/−/ Mice. *J Clin Invest* (2003) 111:1147–60. doi: 10.1172/JCI16537

126. Stoffels DA, Farrow J, Clarke WL, Habener JF. Early-Onset Type-II Diabetes Mellitus (MODY4) Linked to IF1. *Nat Genet* (1997) 17:138–9. doi: 10.1038/ng1097-138

127. Shih DQ, Heimesaat M, Kuwajima S, Stein R, Wright CVE, Stoffel M. Profound Defects in Pancreatic Beta-Cell Function in Mice With Combined

128. Zegre Amorim M, Houghton JAL, Carmo S, Salva IS, Pita A, Pereira-da-Silva L. Mitchell-RIley Syndrome: A Novel Mutation in RFX6 Gene. *Case Rep Genet* (2015) 2015:973201. doi: 10.1155/2015/973201

129. Gradwohl G, Dierich A, LeMeur M, Guillotet F. Neurogenin3 Is Required for the Development of the Four Endocrine Cell Lineages of the Pancreas. *Proc Natl Acad Sci* (2000) 97:1607. doi: 10.1073/pnas.97.4.1607
Heterozygous Mutations in Pdx-1, Hnf-1alpha, and Hnf-3beta. *Proc Natl Acad Sci* (2002) 99:3818. doi: 10.1073/pnas.062660599

148. Fajans SS, Bell GI, Polonsky KS. Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young. *New Engl J Med* (2001) 345:971–80. doi: 10.1056/NEJMra002168

149. Krapp A, Knöfler M, Ledermann B, Bürki K, Berney C, Zoerkler N, et al. The Bhlh Protein PTF1-P48 Is Essential for the Formation of the Exocrine and the Correct Spatial Organization of the Endocrine Pancreas. *Genes Dev* (1998) 12:3752–63. doi: 10.1101/gad.12.23.3752

150. Burlison JS, Long Q, Fujitani Y, Wright CV, Magnuson MA. Pdx-1 and Ptf1a Concurrently Determine Fate Specification of Pancreatic Multipotent Progenitor Cells. *Dev Biol* (2008) 316:74–86. doi: 10.1016/j.ydbio.2008.01.011

151. Weedon MN, Cebola I, Patch AM, Flanagan SE, De Franco E, Caswell R, et al. Recessive Mutations in a Distal PTF1A Enhancer Cause Isolated Pancreatic Agenesis. *Nat Genet* (2014) 46:61–4. doi: 10.1038/ng.2826

152. Balboa D, Saarimäki-Vire J, Borshagowski D, Survila M, Pulkki P, Galli E, et al. Insulin Mutations Impair Beta-Cell Development in a Patient-Derived Ipsc Model of Neonatal Diabetes. *Elife* (2018) 7:e38519. doi: 10.7554/eLife.38519

153. Ma S, Viola R, Sui L, Cherubini V, Barbetti F, Egli D. β Cell Replacement After Gene Editing of a Neonatal Diabetes-Causing Mutation at the Insulin Locus. *Stem Cell Rep* (2018) 11:1407–15. doi: 10.1016/j.stemcr.2018.11.006

154. Saarimäki-Vire J, Balboa D, Russell MA, Saarikettu J, Kinnunen M, Keskiöalo S, et al. An Activating STAT3 Mutation Causes Neonatal Diabetes Through Premature Induction of Pancreatic Differentiation. *Cell Rep* (2017) 19:281–94. doi: 10.1016/j.celrep.2017.03.055

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Burgos, Vallier and Rodríguez-Seguí. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.